GSK Brings HCV Assets Into Its Infectious Diseases R&D Center
Executive Summary
Each week, "The Pink Sheet" presents commentary on some of the week's most interesting business deals, contributed by the editors of the IN VIVO blog. Visit the blog at 1http://invivoblog.blogspot.com/.
You may also be interested in...
The Risks Of Surrogacy: Egrifta Faces Twofold Challenge At Advisory Committee
Theratechnologies will need to address FDA's concerns about whether a reduction of patients' visceral abdominal fat produced by the HIV lipodystrophy product has clinical meaning and is worth the risks.
The Risks Of Surrogacy: Egrifta Faces Twofold Challenge At Advisory Committee
Theratechnologies will need to address FDA's concerns about whether a reduction of patients' visceral abdominal fat produced by the HIV lipodystrophy product has clinical meaning and is worth the risks.
Tesamorelin Will Get Advisory Committee Review For Treatment Of HIV-Drug Side Effect
Merck-Serono/Theratechnologies' Egrifta would be a first-in-class product for lipodystrophy, which sponsors say is a $1.3 billion market.